CN112638899A - 一类具有免疫调节功能的芳香化合物的制备和应用 - Google Patents

一类具有免疫调节功能的芳香化合物的制备和应用 Download PDF

Info

Publication number
CN112638899A
CN112638899A CN201980051399.7A CN201980051399A CN112638899A CN 112638899 A CN112638899 A CN 112638899A CN 201980051399 A CN201980051399 A CN 201980051399A CN 112638899 A CN112638899 A CN 112638899A
Authority
CN
China
Prior art keywords
group
substituted
unsubstituted
compound
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980051399.7A
Other languages
English (en)
Other versions
CN112638899B (zh
Inventor
张毅
邓建稳
冯志勇
黄磊
江磊
路小丽
尚珂
寿建勇
汪兵
徐雪丽
徐圆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Ennovabio Pharmaceuticals Co Ltd
Original Assignee
Shanghai Ennovabio Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201810865177.6A external-priority patent/CN110790770A/zh
Priority claimed from CN201910503368.2A external-priority patent/CN112062780A/zh
Application filed by Shanghai Ennovabio Pharmaceuticals Co Ltd filed Critical Shanghai Ennovabio Pharmaceuticals Co Ltd
Publication of CN112638899A publication Critical patent/CN112638899A/zh
Application granted granted Critical
Publication of CN112638899B publication Critical patent/CN112638899B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

一种具有式(1)结构的免疫调节作用的芳香化合物、制备方法和其在调节免疫，抑制PD‑1/PD‑L1方面的用途。

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN201980051399.7A 2018-08-01 2019-08-01 一类具有免疫调节功能的芳香化合物的制备和应用 Active CN112638899B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201810865177.6A CN110790770A (zh) 2018-08-01 2018-08-01 一类具有免疫调节功能的芳香胺化合物的制备和应用
CN2018108651776 2018-08-01
CN2019105033682 2019-06-11
CN201910503368.2A CN112062780A (zh) 2019-06-11 2019-06-11 一类具有免疫调节功能的芳香化合物的制备和应用
PCT/CN2019/098925 WO2020025030A1 (zh) 2018-08-01 2019-08-01 一类具有免疫调节功能的芳香化合物的制备和应用

Publications (2)

Publication Number Publication Date
CN112638899A true CN112638899A (zh) 2021-04-09
CN112638899B CN112638899B (zh) 2023-09-05

Family

ID=69231502

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980051399.7A Active CN112638899B (zh) 2018-08-01 2019-08-01 一类具有免疫调节功能的芳香化合物的制备和应用

Country Status (4)

Country Link
US (1) US20210347785A1 (zh)
EP (1) EP3831823A4 (zh)
CN (1) CN112638899B (zh)
WO (1) WO2020025030A1 (zh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017289038B2 (en) 2016-06-27 2021-07-22 Chemocentryx, Inc. Immunomodulator compounds
CA3070794A1 (en) 2017-07-28 2019-01-31 Chemocentryx, Inc. Immunomodulator compounds
EP3664793B1 (en) 2017-08-08 2022-06-29 ChemoCentryx, Inc. Macrocyclic immunomodulators
WO2019165043A2 (en) 2018-02-22 2019-08-29 Chemocentryx, Inc. Indane-amines as pd-l1 antagonists
JP2022531970A (ja) 2019-05-15 2022-07-12 ケモセントリックス，インコーポレイティド Ｐｄ－ｌ１疾患治療用のトリアリール化合物
MA55325A (fr) 2019-06-20 2022-04-27 Chemocentryx Inc Composés pour le traitement de maladies pd-l1
KR20220034829A (ko) 2019-07-10 2022-03-18 케모센트릭스, 인크. Pd-l1 억제제로서의 인단
BR112022006018A2 (pt) 2019-10-16 2022-07-12 Chemocentryx Inc Heteroaril-bifenil amidas para o tratamento de doenças relacionadas à pd-l1
CA3152714A1 (en) * 2019-10-16 2021-04-22 Pingchen Fan Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases
BR112022010924A2 (pt) 2019-12-06 2022-09-06 Vertex Pharma Tetra-hidrofuranos substituídos como moduladores de canais de sódio
WO2022221227A1 (en) 2021-04-13 2022-10-20 Nuvalent, Inc. Amino-substituted heterocycles for treating cancers with egfr mutations
PE20241335A1 (es) 2021-06-04 2024-07-03 Vertex Pharma N-(hidroxialquil (hetero)aril) tetrahidrofurano carboxamidas como moduladores de canales de sodio
CN115433210A (zh) * 2021-06-04 2022-12-06 上海轶诺药业有限公司 一类具有免疫调节功能的化合物的制备和应用

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004046133A1 (en) * 2002-11-15 2004-06-03 Merck Sharp & Dohme Limited Amino-heterocycles as vr-1 antagonists for treating pain
WO2005026129A1 (en) * 2003-09-15 2005-03-24 Gpc Biotech Ag Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
WO2014052699A1 (en) * 2012-09-28 2014-04-03 Cephalon, Inc. Azaquinazoline inhibitors of atypical protein kinase c
WO2017112730A1 (en) * 2015-12-22 2017-06-29 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2017184775A1 (en) * 2016-04-19 2017-10-26 The Regents Of The University Of California Erbb inhibitors and uses thereof
WO2018026971A1 (en) * 2016-08-03 2018-02-08 Arising International, Llc Symmetric or semi-symmetric compounds useful as immunomodulators
WO2018119266A1 (en) * 2016-12-22 2018-06-28 Incyte Corporation Benzooxazole derivatives as immunomodulators
WO2018119263A1 (en) * 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds derivatives as pd-l1 internalization inducers
WO2018119286A1 (en) * 2016-12-22 2018-06-28 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004046133A1 (en) * 2002-11-15 2004-06-03 Merck Sharp & Dohme Limited Amino-heterocycles as vr-1 antagonists for treating pain
WO2005026129A1 (en) * 2003-09-15 2005-03-24 Gpc Biotech Ag Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
WO2014052699A1 (en) * 2012-09-28 2014-04-03 Cephalon, Inc. Azaquinazoline inhibitors of atypical protein kinase c
WO2017112730A1 (en) * 2015-12-22 2017-06-29 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2017184775A1 (en) * 2016-04-19 2017-10-26 The Regents Of The University Of California Erbb inhibitors and uses thereof
WO2018026971A1 (en) * 2016-08-03 2018-02-08 Arising International, Llc Symmetric or semi-symmetric compounds useful as immunomodulators
WO2018119266A1 (en) * 2016-12-22 2018-06-28 Incyte Corporation Benzooxazole derivatives as immunomodulators
WO2018119263A1 (en) * 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds derivatives as pd-l1 internalization inducers
WO2018119286A1 (en) * 2016-12-22 2018-06-28 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators

Also Published As

Publication number Publication date
EP3831823A1 (en) 2021-06-09
EP3831823A4 (en) 2022-04-27
WO2020025030A1 (zh) 2020-02-06
CN112638899B (zh) 2023-09-05
US20210347785A1 (en) 2021-11-11

Similar Documents

Publication Publication Date Title
CN112638899A (zh) 一类具有免疫调节功能的芳香化合物的制备和应用
CN112159405B (zh) 吡啶并嘧啶酮类化合物及其应用
CN114846015B (zh) 用作t细胞激活剂的经取代的杂芳基化合物
CN110790770A (zh) 一类具有免疫调节功能的芳香胺化合物的制备和应用
EP3917927A1 (en) Immunomodulators, compositions and methods thereof
KR101816942B1 (ko) 키누레닌 생성 억제 작용을 갖는 함질소 복소환 화합물
CN112638900A (zh) 一类具有免疫调节功能的含n杂环化合物的制备和应用
CN113637005A (zh) 用于癌症治疗的kras抑制剂
KR20180083421A (ko) 단백질 키나아제 억제제 및 이의 제조방법과 의학적 용도
CA3149482A1 (en) Bis-[n-((5-carbamoyl)-1h-benzo[d]imidazol-2-yl)-pyrazol-5-carboxamide] derivatives and related compounds as sting (stimulator of interferon genes) agonists for the treatment of cancer
WO2014113191A1 (en) Hedgehog pathway signaling inhibitors and therapeutic applications thereof
KR20220119455A (ko) T 세포 활성화제로서 유용한 치환된 비시클릭 피페리딘 유도체
KR20220158256A (ko) 암의 치료를 위한 치환된 옥소이소인돌린 화합물
CN110156656B (zh) 五元杂芳环衍生物、其制备方法、药物组合物及应用
TW202136242A (zh) Smarca降解劑及其用途
CN113336747A (zh) 新型hpk1抑制剂及其制备方法和应用
CN117295737A (zh) Hpk1拮抗剂和其用途
TW202227063A (zh) 治療癌症之方法
CN114641474B (zh) 一类具有免疫调节功能的含n杂环化合物的制备和应用
WO2023104043A1 (zh) 一种抗凋亡蛋白bcl-2抑制剂、药物组合物及其应用
CN112062780A (zh) 一类具有免疫调节功能的芳香化合物的制备和应用
CN115433210A (zh) 一类具有免疫调节功能的化合物的制备和应用
CN117157284A (zh) Ctla-4小分子降解剂及其应用
US20240262822A1 (en) Wdr5 inhibitors and modulators
CN116490069A (zh) Stat降解剂和其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant